Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

endocrine · Mechanism Report

Can levothyroxine absorption vary with timing, food, gastrointestinal conditions, and interacting supplements?

Levothyroxine absorption can vary enough to cause unstable thyroid exposure and TSH changes even when the prescribed dose stays the same.

SupportedSeptember 30, 20265 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Levothyroxine absorption can vary with administration timing, food, gastrointestinal conditions, and interacting medications or supplements, producing unstable thyroid exposure despite an unchanged dose.

laying out figure…
All 4 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says levothyroxine absorption is sensitive to when it is taken, what it is taken with, and whether other medicines, supplements, or gastrointestinal conditions are present. The mechanism framing is that these factors alter tablet absorption and can change effective thyroid hormone exposure without any change in the written dose.

Verified conclusion

Levothyroxine has a narrow practical margin for administration-related variability: the prescribed dose may remain unchanged while the absorbed dose, and therefore TSH stability, changes substantially.

Clinical evidence

  • Fasting tablet administration—ideally with water 60 minutes before breakfast or coffee—is recommended to support reproducible absorption. An alternative is bedtime dosing at least 3 hours after the evening meal.
  • Taking levothyroxine with breakfast is associated with higher and more variable TSH than fasting or adequately post-meal bedtime use. Food and coffee can reduce tablet absorption, so inconsistent day-to-day timing can cause fluctuating biochemical thyroid control without a prescription change.
  • Calcium and iron supplements can bind levothyroxine in the gastrointestinal tract; separating them from levothyroxine by about 4 hours is generally recommended. Proton-pump inhibitors may impair tablet absorption through reduced gastric acidity.

Gastrointestinal and mechanistic considerations

  • H. pylori–associated gastritis, atrophic gastritis, and celiac disease can reduce levothyroxine absorption and increase dose requirements. When an underlying disorder is treated, absorption may improve and the formerly appropriate dose can become excessive unless thyroid tests are reassessed.
  • The relevant mechanisms include direct intestinal binding by calcium or iron and altered gastric conditions affecting tablet dissolution and subsequent absorption.
  • Oral semaglutide increased total T4 exposure by 33% in a small healthy-volunteer pharmacokinetic study using a single supratherapeutic levothyroxine dose. This finding did not establish effects on TSH or routine long-term dosing.

Bottom line

  • Unstable TSH or changing levothyroxine requirements should prompt review of dosing timing, meals/coffee, calcium or iron, acid-suppressing therapy, and gastrointestinal disease—not just automatic dose adjustment.

References

  1. ETA guidelines for the use of levothyroxine sodium preparations in ... — pmc.ncbi.nlm.nih.gov ↗
  2. Guidelines for the Treatment of Hypothyroidism - PMC - NIH — pmc.ncbi.nlm.nih.gov ↗
  3. Levothyroxine Interactions with Food and Dietary ... - PMC - NIH — pmc.ncbi.nlm.nih.gov ↗
  4. ATA Guidelines Tools - ATA Hypothyroidism Pocket Card — eguideline.guidelinecentral.com ↗
  5. SAT-140 A Drug-Drug Interaction Trial of Oral Semaglutide with Levothyroxine and Multiple Coadministered Tablets — academic.oup.com ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible17 sourcesCan MCM8, FSHB, and FSHR variants influence menopause timing and ovarian hormone response?→Plausible4 sourcesDoes menopause lead to persistently low progesterone?→